Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Respiratory syncytial virus infection treating compound and preparation method and application thereof

A syncytial virus and virus infection technology, applied in the field of biomedicine, can solve problems such as side effects of patients

Active Publication Date: 2016-06-01
SHANGHAI MEDUSA BIOTECHNOLOGY CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These properties may cause severe side effects in treated patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Respiratory syncytial virus infection treating compound and preparation method and application thereof
  • Respiratory syncytial virus infection treating compound and preparation method and application thereof
  • Respiratory syncytial virus infection treating compound and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Preparation of a cyclopamine (CPM) analogue S1-2, see appendix figure 1 , attached figure 2 And attached image 3 , the preparation process is as follows:

[0084] 1) Preparation of intermediates. First, cyclopamine (498.06mg, 1.21mmol / L, 1.00eq) and triethylamine (489.76mg, 4.84mmol / L, 4.00eq) were dissolved in dry dichloromethane DCM (4mL); Trifluoroacetic anhydride (762.41 mg, 3.63 mmol, 3.00 eq) dissolved in DCM (1 mL) was added to the solution at °C; third, the reaction mixture was slowly heated to 15 °C and kept stirring for 16 h; fourth, the solution was passed through the liquid Phase chromatography-mass spectrometry (LCMS) showed that the starting material was completely consumed, the target product RT=0.996min, 25%, the by-product pertrifluoroacetic acid RT=1.125min, 47%; the fifth, the reaction mixture was concentrated, the residue Diluted with methanol (15 mL); sixth, the resulting suspension was heated to 70 °C and incubated for 1 hour; seventh, the re...

Embodiment 2

[0135] Preparation of a cyclopamine (CPM) analog S1-4, see appendix figure 1 , attached figure 2 And attached image 3 , the preparation process is as follows:

[0136] 1) Preparation of intermediates. The preparation process is the same as in Example 1.

[0137] 2) Preparation of compound S1-4. The preparation process is the same as in Example 1.

[0138] 3) To test the inhibitory effect of S1-4 on RSV replication. The test process is the same as in Example 1. See attached Figure 4 , it can be seen that the maximum inhibitory ratio of compound S1-4 to the replication ability of respiratory syncytial virus (RSV) is 88%.

[0139] 4) Test the inhibitory effect of S1-4 on the Hn signaling pathway. The test process is the same as in Example 1. See attached Figure 5 , it can be seen that the inhibitory effect of cyclopamine (CPM) analog S1-4 on gene expression is not significant, and the inhibition rate is only 5%. These data suggest that the anti-respiratory syncyti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a respiratory syncytial virus infection treating compound and a preparation method and application thereof. The compound refers to chemical analogues of cyclopamine and is characterized by suppressing replication of respiratory syncytial virus without suppressing Hedgehog signal pathway. The preparation method includes synthesizing the chemical analogues of cyclopamine in a medicinal chemistry way and then screening the analogues by means of in-vitro tests performed in parallel. The compound is applied to treatment of respiratory virus infection, paramyxovirus infection, respiratory syncytial virus infection, and capillary bronchitis, pneumonia and tympanitis which are all caused by respiratory syncytial virus, is free of toxic and side effect to cause fetal anomaly, overcomes teratogenicity of cyclopamine, and fills the blank of drugs especially pediatric drugs for treating respiratory syncytial virus infection.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a compound for treating respiratory syncytial virus infection and its preparation method and application. Background technique [0002] Bronchiolitis is a serious lower respiratory infectious disease mainly caused by viruses of the Paramyxoviridae family. Human respiratory syncytial virus (Human respiratory syncytial virus, hRSV) is the main cause of disease in children under 2 years old, the elderly, immunocompromised and transplant patients. To date, there are no vaccines or approved effective drugs to prevent or treat hRSV infection. The immunological drug Palivizumab is approved for use in high-risk patients, which includes only premature infants and infants with primary disease. The broad-spectrum antiviral drug ribavirin, a small molecule, can be used to treat infections, but has considerable side effects and limited efficacy. Over the past decade, several drug candi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07J69/00A61K31/58A61P31/12A61P31/14A61P11/00A61P27/16
CPCC07J69/00C07J71/0005A61K31/4355A61P31/14A61K31/58
Inventor R·艾德铭曹晶晶
Owner SHANGHAI MEDUSA BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com